2.68
Outlook Therapeutics Inc stock is traded at $2.68, with a volume of 3.68M.
It is up +11.20% in the last 24 hours and up +28.85% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$2.41
Open:
$2.46
24h Volume:
3.68M
Relative Volume:
3.50
Market Cap:
$89.96M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.67
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
+14.53%
1M Performance:
+28.85%
6M Performance:
+71.79%
1Y Performance:
-62.62%
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
OTLK
Outlook Therapeutics Inc
|
2.68 | 118.70M | 0 | -51.50M | -47.10M | -4.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
Jul-13-23 | Initiated | CapitalOne | Overweight |
Apr-03-23 | Initiated | Guggenheim | Buy |
Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-31-22 | Initiated | BTIG Research | Buy |
Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
May-16-19 | Initiated | Oppenheimer | Outperform |
Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Certain Warrants of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2025. - MarketScreener
Will Outlook Therapeutics (OTLK) Stocks Rise? - StocksToTrade
Outlook Therapeutics Reports Q3 Revenue - AOL.com
Outlook Therapeutics Inc. Recovery Likely Here’s What Data ShowsJuly 2025 Summary & High Win Rate Trade Alerts - classian.co.kr
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail
Can Outlook Therapeutics Inc. Escape Recent Bear ChannelJuly 2025 Levels & Target Return Focused Stock Picks - 선데이타임즈
Can Outlook Therapeutics Inc. Overcome Bearish SentimentEarnings Overview Summary & Low Drawdown Trading Techniques - newsyoung.net
Outlook Therapeutics (OTLK.O) Surges 17.7%—What’s Fueling the Intraday Spike? - AInvest
Outlook Therapeutics Inc. (OTLK) Soars 11.97% on FDA Decision Anticipation - AInvest
Outlook Therapeutics Posts Q3 2025 Loss Amid High Operating Costs—Market Impact and Earnings Backtest Insights - AInvest
Navigating Trade Turbulence: Outlook Therapeutics Faces Challenges from Global Trade Policies. - AInvest
Chardan Capital Maintains Neutral Rating for Outlook Therapeutics with $3.00 Price Target - AInvest
Outlook Therapeutics Reports Q3 2025 Earnings and Milestones - MSN
Outlook Therapeutics Posts Another Loss in Q3 2025 Earnings — Market Impact Remains Mixed - AInvest
Navigating Trade Turbulence: Outlook Therapeutics’ Struggle with Global Trade Policies - The Globe and Mail
What makes Outlook Therapeutics Inc. stock attractive today2025 Major Catalysts & AI Enhanced Trading Signals - sundaytimes.kr
Outlook Therapeutics Inc. Sees Relief Buying After Extended DropJuly 2025 Retail & Free Fast Entry Momentum Trade Alerts - metal.it
Published on: 2025-08-16 19:04:04 - metal.it
Outlook Therapeutics: Pivoting from R&D to Commercialization with LYTENAVA™ in Europe and FDA Approval on Horizon - AInvest
Outlook Therapeutics (OTLK) Maintains Rating by Chardan Capital - GuruFocus
Chardan Capital raises Outlook Therapeutics' PT to $3, maintains Neutral rating. - AInvest
Outlook Therapeutics shares rise 4.12% premarket after reporting financial results for the third quarter. - AInvest
Outlook Therapeutics Posts Q3 Revenue of $1.5mln, Meeting Estimates, and First-Ever Commercial Sales in Europe. - AInvest
Outlook Therapeutics Inc Reports Q3 2025 Earnings: EPS of -$0.55 - GuruFocus
Outlook Therapeutics Q3 FY2025 Financial Results and Corporate Update - TradingView
Outlook Therapeutics reports Q3 adjusted EPS (44c) vs. (83c) last year - TipRanks
Outlook Therapeutics at a Strategic Inflection Point: Regulatory and Commercial Catalysts for Value Creation in the $4B+ Anti-VEGF Market - AInvest
Outlook Therapeutics reports Q3 net loss of $20.2mln, $1.5mln revenue. - AInvest
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire
Outlook's Eye Drug LYTENAVA Launches in Europe as Critical FDA Decision Approaches - Stock Titan
Will Outlook Therapeutics Inc. Hold Gains Into CloseEntry Point & Community Verified Watchlist Alerts - kangso.co.kr
Reversal Traders Monitor Outlook Therapeutics Inc. for EntryChart Breakout Buy Signal Detection Confirmed - 선데이타임즈
Outlook Therapeutics, Inc. shares rise 1.94% after-hours due to positive market sentiment. - AInvest
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024OTLK - ACCESS Newswire
Outlook Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Published on: 2025-08-04 15:25:16 - metal.it
What are analysts’ price targets for Outlook Therapeutics Inc. in the next 12 monthsUnlock high-yield investment opportunities - Jammu Links News
What institutional investors are buying Outlook Therapeutics Inc. stockTriple-digit profit margins - Jammu Links News
What are the latest earnings results for Outlook Therapeutics Inc.Game-changing capital returns - Jammu Links News
What is the dividend policy of Outlook Therapeutics Inc. stockFree Capital Allocation Plans - Jammu Links News
How volatile is Outlook Therapeutics Inc. stock compared to the marketExceptional portfolio growth - Jammu Links News
When is Outlook Therapeutics Inc. stock expected to show significant growthExplosive portfolio gains - Jammu Links News
Is Outlook Therapeutics Inc. a good long term investmentUnrivaled growth potential - Jammu Links News
How strong is Outlook Therapeutics Inc. company’s balance sheetCapitalize on fast-growing stocks today - Jammu Links News
What is the risk reward ratio of investing in Outlook Therapeutics Inc. stockFree Stock Chart Pattern Guide - Jammu Links News
What makes Outlook Therapeutics Inc. stock price move sharplyInvest confidently with expert support - Jammu Links News
What catalysts could drive Outlook Therapeutics Inc. stock higher in 2025Achieve breakthrough performance in the market - Jammu Links News
Should I hold or sell Outlook Therapeutics Inc. stock in 2025Capitalize on emerging market sectors - Jammu Links News
How does Outlook Therapeutics Inc. generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News
What is Outlook Therapeutics Inc. company’s growth strategyPre Market Recommendation With Low Risk - Jammu Links News
Outlook Therapeutics, Inc. shares rise 1.95% premarket after Eli Lilly's Mounjaro shows heart benefits in a head-to-head study. - AInvest
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):